Alectinib, Free Base

Alectinib, Free Base
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
LC-A-2300_25mg 25 mg -

3 - 15 Werktage*

94,00 €
LC-A-2300_50mg 50 mg -

3 - 15 Werktage*

110,00 €
LC-A-2300_100mg 100 mg -

3 - 15 Werktage*

144,00 €
LC-A-2300_200mg 200 mg -

3 - 15 Werktage*

198,00 €
LC-A-2300_250mg 250 mg -

3 - 15 Werktage*

223,00 €
LC-A-2300_500mg 500 mg -

3 - 15 Werktage*

335,00 €
LC-A-2300_1g 1 g -

3 - 15 Werktage*

472,00 €
LC-A-2300_2g 2 g -

3 - 15 Werktage*

823,00 €
LC-A-2300_5g 5 g -

3 - 15 Werktage*

1.461,00 €
 
Soluble in DMSO.. Alectinib, also known as CH 5424802, is a potent, selective, and orally... mehr
Produktinformationen "Alectinib, Free Base"
Soluble in DMSO.. Alectinib, also known as CH 5424802, is a potent, selective, and orally available ALK inhibitor (IC50 = 1.9 nM) and has weak or no inhibition against 24 other tested protein kinases. It has selective antitumor activity against cancers with ALK gene alterations, including non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. It also blocked ALK L1196M, which corresponds to the gatekeeper mutation giving common resistance to kinase inhibitors, and prevented EML4-ALK L1196M-driven cell growth. Sakamoto H., et al. 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.' Cancer Cell 19: 679-690 (2011). Alectinib reduced the tumor size in EML4-ALK-positive xenograft tumors that was not able to regress fully during treatment with crizotinib. Alectinib also inhibited the growth of some EML4-ALK mutant-driven tumors, such as the G1269A model. Kodama T., et al. 'Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.' Cancer Lett. 351: 215-221 (2014). Two ALK mutations, a V1180L gatekeeper mutation from the cell line model and I1171T mutation from a patient, were found to develop resistance to alectinib and to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Katayama R., et al. 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.' Clin. Cancer Res. 20: 5686-5696 (2014). This research compound is the free acid form of alectinib, we also offer the HCl salt form of alectinib, please see Cat. No. A-2311, Alectinib, Hydrochloride Salt. The free base form of alectinib is used for some or all alectinib formulations for use in humans.
Schlagworte: CH 5424802
Hersteller: LC Laboratories
Hersteller-Nr: A-2300

Eigenschaften

Anwendung: Antineoplastic, Anaplastic lymphoma kinase (ALK) inhibitor
MW: 482.62 D
Formel: C30H34N4O2
Reinheit: >99%
Format: Solid

Datenbank Information

CAS : 1256580-46-7| Passende Produkte
KEGG ID : K05119 | Passende Produkte

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +20°C (International: +20°C)
Signalwort: Warning
GHS-Piktogramme:
H-Sätze: H302+H312+H332
P-Sätze: P262
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Alectinib, Free Base"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen